Manuscripts and Publications

Filters: Author is Couper, David  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
P
Fawzy A, Woo H, Balasubramanian A, Barjaktarevic I, R Barr G, Bowler RP, Comellas AP, Cooper CB, Couper D, Criner GJ et al..  2021.  Polycythemia is Associated with Lower Incidence of Severe COPD Exacerbations in the SPIROMICS Study.. Chronic Obstr Pulm Dis. 8(3):326-335.
Angelini ED, Yang J, Balte PP, Hoffman EA, Manichaikul AW, Sun Y, Shen W, Austin JHM, Allen NB, Bleecker ER et al..  2023.  Pulmonary emphysema subtypes defined by unsupervised machine learning on CT scans. Thorax.
R
Fortis S, Comellas AP, Bhatt SP, Hoffman EA, Han MK, Bhakta NR, Paine R, Ronish B, Kanner RE, Dransfield M et al..  2021.  Ratio of FEV/Slow Vital Capacity of < 0.7 Is Associated With Clinical, Functional, and Radiologic Features of Obstructive Lung Disease in Smokers With Preserved Lung Function.. Chest. 160(1):94-103.
Baugh AD, Shiboski S, Hansel NN, Ortega V, Barjaktarevic I, R Barr G, Bowler R, Comellas AP, Cooper CB, Couper D et al..  2022.  Reconsidering the Utility of Race-Specific Lung Function Prediction Equations.. Am J Respir Crit Care Med. 205(7):819-829.
LaFon DC, Woo H, Fedarko N, Azar A, Hill H, Tebo AE, Martins TB, Han MK, Krishnan JA, Ortega VE et al..  2023.  Reduced quantity and function of pneumococcal antibodies are associated with exacerbations of COPD in SPIROMICS.. Clin Immunol. 250:109324.
Martinez CH, Murray S, R Barr G, Bleecker E, Bowler RP, Christenson SA, Comellas AP, Cooper CB, Couper D, Criner GJ et al..  2017.  Respiratory Symptoms Items from the COPD Assessment Test Identify Ever-Smokers with Preserved Lung Function at Higher Risk for Poor Respiratory Outcomes. An Analysis of the Subpopulations and Intermediate Outcome Measures in COPD Study Cohort.. Ann Am Thorac Soc. 14(5):636-642.
S
Yee N, Markovic D, Buhr RG, Fortis S, Arjomandi M, Couper D, Anderson WH, Paine R, Woodruff PG, Han MK et al..  2022.  Significance of FEV/FEV in Recognition of Early Airway Disease in Smokers at Risk of Development of COPD: Analysis of the SPIROMICS Cohort.. Chest. 161(4):949-959.
Pratte KA, Curtis JL, Kechris K, Couper D, Cho MH, Silverman EK, DeMeo DL, Sciurba FC, Zhang Y, Ortega VE et al..  2021.  Soluble receptor for advanced glycation end products (sRAGE) as a biomarker of COPD.. Respir Res. 22(1):127.
Sieren JP, Newell JD, R Barr G, Bleecker ER, Burnette N, Carretta EE, Couper D, Goldin J, Guo J, Han MK et al..  2016.  SPIROMICS Protocol for Multicenter Quantitative Computed Tomography to Phenotype the Lungs.. Am J Respir Crit Care Med. 194(7):794-806.

Pages